An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia
Abstract: B-lineage acute lymphoblastic leukemia (B-ALL) therapy is being transformed by therapies targeting antigens such as CD19, CD20, and CD22 on the surface of B-ALL cells. Moreover, having therapies targeting these different B-ALL antigens has helped address challenges associated with both int...
Saved in:
| Main Authors: | Peter M. Gordon, Robin L. Williams, Jason Ostergaard, Keegan C. Lee, Hannah N. Bui, Joseph M. Muretta, Bridget S. Wilson, Thomas Beder, Claudia D. Baldus, Luke Lambert, Benjamin E. Deonovic, Timothy Singleton, Sarah K. Tasian, Stuart S. Winter |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Blood Neoplasia |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S295032802500055X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Blinatumomab in pediatric B-acute lymphoblastic leukemia
by: Yifang Cheng, et al.
Published: (2025-07-01) -
Primary B-cell lymphoblastic lymphoma of the ovary
by: Anjana Joel, et al.
Published: (2018-01-01) -
Acute B-cell lymphoblastic leukaemia presenting as acute hepatitis
by: I. Jenosha, et al.
Published: (2025-03-01) -
Secondary Histiocytic Sarcoma in a Pre-B-Acute Lymphoblastic Leukemia
by: Sharanya Ramakrishnan, et al. -
Evaluation of Haemophilus influenzae Type B Conjugate Vaccine (Meningococcal Protein Conjugate) in Canadian Infants
by: David W Scheifele, et al.
Published: (1994-01-01)